RARA CRAFT DATABASE for FDA Medical Devices
510(k)K261869

FDA DEVICE FACTS

Integrity Retractable Implant Inserter (6000127)

Anika Therapeutics, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATESeptember 17, 2026PRODUCT CODEMBI

Indications for use

The Integrity Bone Fixation System is indicated for the fixation of soft tissue grafts or reinforcement meshes to bone during rotator cuff repairs. Device Characteristics

Integrity Retractable Implant Inserter Integrity Bone Staple Fixation System (Bone Staple Delivery Instrument) 510(k) clearance Subject Device K223860 Manufacturer Anika Therapeutics, Inc. Anika Therapeutics, Inc. Regulation 21 CFR 888.3040 21 CFR 888.3040 Class 2 2 Product Code MBI MBI Indication for Use The Integrity Bone Staple Fixation System is indicated for the fixation of soft tissue grafts or reinforcement meshes to bone during rotator cuff repairs. The Integrity Bone Staple Fixation System is indicated for the fixation of soft tissue grafts or reinforcement meshes to bone during rotator cuff repairs. Materials Stainless steel, polymer resins Stainless steel, polycarbonate, ABS Single use Yes Yes Sterility Sterile, Gamma Sterile, Gamma Shelf-life 1-year 1-year

Non-clinical Testing

Non-clinical testing was conducted to evaluate the biocompatibility and performance of the subject device. The results of the testing were assessed against the predicate device to determine substantial equivalency for design, performance, and safety. Cytotoxicity, sensiti zation, irritation, acute systemic toxicity, and m aterial mediated pyrogenicity tes ting were performed to evaluate biocompatibility. Instrument mechanical performance and visual/physical inspection determined the performance of the subject device.

Final devices were subjected to bacterial endotoxin testing in accordance with USP <85>.

Method Test Article LAL Sensitivity Endotoxin Limit Results USP <85> Gel Clot Endotoxin Ten (10) disassembled devices, each submerged in 100ml LAL reagent water (LRW), extracted for one (1) hour 0.03 EU/mL <20 EU/device <12 EU/device

Requirement of USP met.

Clinical Data Clinical testing was deemed not necessary for demonstrating substantial equivalence to the predicate device.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: October 7, 2026